Thousands more patients with multiple sclerosis in England will soon be able to access Merck KGaA's take-at-home tablet Mavenclad, reducing their need for clinic visits. New guidance (PDF ...

No cruel intentions here: Merck KGaA’s U.S. pharma arm has recruited actor Selma Blair for a collaboration around multiple sclerosis treatment Mavenclad. Blair, best known for her roles in turn ...

Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence (NICE) to treat a broader group of multiple sclerosis (MS) patients. The ...

The health service is thought to be the first in Europe to widely rollout cladribine, also known as Mavenclad and made by Merck. It has been approved by the National Institute for Health and Care ...

The health service is thought to be the first in Europe to widely rollout cladribine, also known as Mavenclad and made by Merck. It has been approved by the National Institute for Health and Care ...

The effort is designed to raise awareness of RMS — and which is the most common form of MS — as well as the treatment option of Mavenclad (cladribine) tablets, which are produced by the healthcare ...

Europe’s CHMP top scientific committee gave a positive opinion for approval to cladribine, with the proposed trade name Mavenclad, for relapsing forms of MS with high disease activity.

Merck KGaA (TG:MRK) cut its growth forecast for its healthcare division, which includes multiple sclerosis drug Mavenclad and cancer treatment Bavencio. The company also lowered its growth target ...

Laura Thomas, Head of Policy at the MS Society, said: “It’s great news that NICE have recommended the disease modifying treatment (DMT) cladribine (Mavenclad) as an option for those with active ...